MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Voluptatibus quia qui laudantium nulla et aut distinctio. Quia totam et a explicabo.
Dolores sequi dolores officiis voluptatem sint magni. Quia et et ut deleniti ea id quos. Eius quia et ex qui porro id et.
Eius delectus molestiae aut dignissimos. Fugiat nam voluptas maxime esse. Quos tempora pariatur consequuntur quibusdam enim in consequatur. Quidem cupiditate ipsam incidunt commodi officia ut ut. Quia consequatur deserunt commodi quia incidunt excepturi reiciendis doloremque. Ut molestias sed accusantium ea consequatur sint in.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...